Paliperidone for irritability in adolescents and young adults with autistic disorder

Psychopharmacology

Volumn 223, Issue 2, 2012, Pages 237-245

  Stigler, Kimberly A ^a   Mullett, Jennifer E ^a   Erickson, Craig A ^a   Posey, David J ^a   McDougle, Christopher J ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Autistic disorder; Irritability; Paliperidone

Indexed keywords

AMITRIPTYLINE; AMPHETAMINE; BENZATROPINE; BENZATROPINE MESILATE; CITALOPRAM; CLONIDINE; FLUOXETINE; GABAPENTIN; GUANFACINE; MELATONIN; METHYLPHENIDATE; PALIPERIDONE; RISPERIDONE; TRAZODONE; VALPROATE SEMISODIUM;

ADOLESCENT; ADULT; AGE; AKATHISIA; ARTICLE; AUTISM; BEDTIME DOSAGE; BODY MASS; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAM; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HEART RATE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; INCREASED APPETITE; INSOMNIA; IRRITABILITY; IRRITABILITY ABERRANT BEHAVIOR CHECKLIST; MALE; MORNING DOSAGE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RATING SCALE; RHINITIS; SCHOOL CHILD; SEDATION; SEX RATIO; SIDE EFFECT; TIC; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IRRITABLE MOOD; ISOXAZOLES; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866737066     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2711-3     Document Type: Article

References (42)

1. Aman MG, Singh NN, Stewart AW, Field CJ (1985) The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-91
2. Arnold LE, Aman MG, Martin A, Collier-Crespin A, Vitiello B, Tierney E, Asarnow R, Bell-Bradshaw F, Freeman BJ, Gates-Ulanet P, Klin A, McCracken JT, McDougle CJ, McGough JJ, Posey DJ, Scahill L, Swiezy NB, Ritz L, Volkmar F (2000) Assessment in multisite randomized clinical trials of patients with autistic disorder: the RUPP autism network. J Autism Dev Disord 30(2):99-111
3. Becker AL, Epperson CN (2006) Female puberty: clinical implications for the use of prolactin-modulating psychotropics. Child Adolesc Psychiatr Clin North America 15:207-20
4. Boom S, Talluri K, Janssens L, Remmerie B, De Meulder M, Rossenu S, van Osselaer N, Eerdekens M, Cleton A (2009) Single-and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol 49:1318-30
5. Brewer HB Jr (2011) Clinical review: the evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab 96:1246-57
6. Brown EC, Aman MG, Havercamp SM (2002) Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education. Res Dev Disabil 23:45-60
7. Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA, Zhu Y, Damaraju CV, Kalali AH, Mahmoud R (2009) Randomized, double-blind, placebo-controlled study of paliperidone extendedrelease and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 166:691-701
8. Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, Turkoz I, Carothers J, Bossie CA, Schooler NR (2010) A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry 71:587-98
9. Chwieduk CM, Keating GM (2010) Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs 70:1295-317
10. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, Metzger LM, Shoushtari CS, Splinter R, Reich W (2003) Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord 33:427-33
11. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M (2007) Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 93:117-30
12. Dremencov E, ElMansariM, Blier P (2007) Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology 194:63-72
13. Emsley R, Berwaerts J, Eerdekens M, Kramer M, Lane R, Lim P, Hough D, Palumbo J (2008) Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 23:343-56
14. Guy W (1976) ECDEU assessment manual for psychopharmacology (NIMH Publication No. 76-338). DHEW, NIMH, Washington, DC
15. Harrington CA, English C (2010) Tolerability of paliperidone: a metaanalysis of randomized, controlled trials. Int Clin Psychopharmacol 25:334-41
16. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M (2007) Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 90:147-61
17. Karlsson P, Dencker E, Nyberg S, Mannaert E, Boom S, Talluri K, Rossenu S, Eriksson B, Eerdekens M, Farde L (2005) Pharmacokinetics and D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Eur Neuropsychopharmacol 15(Suppl 3):S386
18. Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M (2007) Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 27:6-14
19. Lord C, Rutter M, Le Couteur A (1994) Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659-85
20. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110-9
21. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A (2007) Efficacy and safety of paliperidone extendedrelease tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 62:1363-70
22. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ (1997) Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatr 36:685-93
23. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH (1998) A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55:633-41
24. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B (2005) Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162:1142-8
25. McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J (2011) A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 127:e1312-21
26. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M (2008) Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 69:817-29
27. Nicolson R, Awad G, Sloman L (1998) An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatr 37:372-6
28. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533-40
29. Research Units on Pediatric Psychopharmacology Autism Network (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-21
30. Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29-39
31. Robb AS (2010) Managing irritability and aggression in autism spectrum disorders in children and adolescents. Dev Disabil Res Rev 16:258-64
32. Roid GH, Miller LJ (1997) Leiter International Performance Scale-Revised. Stoelting, Wood Dale
33. Roid GH (2003) Stanford-Binet Intelligence Scale, 5th edn. Stoelting, Wood Dale
34. Scahill L, McDougle CJ, Williams SK, Dimitropoulos A, Aman MG, McCracken JT, Tierney E, Arnold LE, Cronin P, Grados M, Ghuman J, Koenig K, Lam KS, McGough J, Posey DJ, Ritz L, Swiezy NB, Vitiello B (2006) Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. Journal of the American Academy of Child & Adolescent Psychiatry. 45, 1114-23
35. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634-41
36. Singh J, Vijapurkar U, Robb AS, Nuamah IF, Hough D (2010) Efficacy, safety, and tolerability of paliperidone extended-release in adolescent patients with schizophrenia (poster). In: American Academy of Child and Adolescent Psychiatry 57th annual meeting
37. Sparrow SS, Cicchetti DV, Balla DA (2005) Vineland Adaptive Behavior Scales, Second Edition (Vineland II). Survey Interview Form/Caregiver Rating Form, Pearson Assessments
38. Stigler KA, McDougle CJ (2008) Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am 17:739-52, vii-viii
39. Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ, McDougle CJ (2009) Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 19:265-74
40. Stigler KA, Erickson CA, Mullett JE, Posey DJ, McDougle CJ (2010) Paliperidone for irritability in autistic disorder. J Child Adolesc Psychopharmacol 20:75-8
41. Vermeir M, Boom S, Naessens I, Talluri K, Eerdekens M (2005) Absorption, metabolism and excretion of a single oral dose of 14Cpaliperidone 1mg in healthy subjects. Eur Neuropsychopharmacol 15 (Suppl 3):S191-S192
42. Vieta E, Nuamah IF,LimP, YuenEC,Palumbo JM,HoughDW, Berwaerts J (2010) A randomized, placebo-and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 12:230-43